Chronic Myeloid Leukemia

Deep Molecular Response to TKI Therapy Predicts Better Survival in CML

A deep molecular response to imatinib, achieved by most chronic myeloid leukemia patients who receive the drug, is predictive of better overall survival, according to a new study.

Chronic Myeloid Leukemia

Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment.

A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.

CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.

A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.

Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.

In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.

Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.


Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.